Behavioral-health facilities sometimes worry about the potential misuse of bleeding-disorder medications or supplies—especially when treating people with substance-use or mental-health concerns.

It’s important to clarify that clotting factor products are not psychoactive substances.
They do not cause euphoria, do not alter mood, and are not painkillers or drugs of abuse.

These medications work by replacing or boosting the missing clotting factor in the blood to stop or prevent bleeding. While they may relieve pain that results from an internal bleed, that’s because they treat the bleed itself—not because they act as a pain medication.

There is no known pattern of abuse or diversion of clotting factor products. They have no street value and are not addictive.

If a person with a bleeding disorder is approved to self-infuse or self-inject, facilities can safely allow this under staff supervision. Oversight ensures that:

• The medication is administered exactly as prescribed, and

• Supplies are used only for their intended medical purpose.

With this model, self-administration can safely and effectively support both medical stability and behavioral-health goals.

Reassuring Facilities About Misuse Concerns

• “I understand your team may be concerned about possible misuse of bleeding-disorder medications or supplies—especially in a behavioral-health setting. That’s completely reasonable, and I’d like to help clarify a few things.”

• “Clotting factor products aren’t psychoactive and aren’t considered drugs of abuse. They don’t produce a ‘high,’ and they’re not painkillers—they just help stop bleeding.”

• “There’s no known pattern of abuse or diversion of these medications. They have no street value and aren’t addictive.”

• “If I’m self-administering, it will always be under staff supervision, so you’ll be able to observe that it’s given exactly as prescribed and that all supplies are used correctly.”

• “This model has worked very successfully in other behavioral-health programs. My treatment team and I are happy to share what’s worked and support your staff in setting up safe, comfortable procedures.”

“If it’s helpful, I can also send you the package insert for my specific medication. It includes official manufacturer information about how the medication works, how to administer it, and how to store it safely.”

Subject: Information About Bleeding-Disorder Medication and Safe Administration

Dear [Facility Contact / Clinical Director / Nursing Lead],

Thank you for taking the time to discuss the use and oversight of my bleeding-disorder medication during treatment. I wanted to share some background information that may help address common concerns about medication safety and misuse.

Bleeding-disorder medications—often called clotting factor products—are not psychoactive and not considered drugs of abuse. They don’t cause euphoria or mind-altering effects, and there is no known pattern of misuse or diversion. These medications have no street value and are used solely to prevent or stop internal bleeding.

If I am approved to self-administer, your staff can safely oversee each infusion to ensure that:

• The medication is administered exactly as prescribed, and

• All supplies are used only for their intended purpose.

This approach has worked well in other behavioral-health settings, allowing patients to continue their treatment safely while maintaining medical stability.

I’m also including a link to the official package insert for my prescribed product. This document provides detailed, manufacturer-approved information on:

• How the medication works

• Administration steps

• Storage requirements

• Safety and handling guidance

Thank you for partnering with me and my treatment team to ensure safe, effective, and coordinated care.

Warm regards,
[Your Name]
[Your Phone / Email]
(optional) [Bleeding-Disorder Treatment Team Contact Info]